


MERIT INSIGHTS

April 2024 Edition

Welcome to the April issue of MERIT Insights, our monthly newsletter. Each month we bring you updates on webinars and trade shows, spotlights on our employees, and important industry news you may have missed.

Q&A FROM OUR OPHTHALMOLOGY WEBINAR

Our ophthalmology webinar "OCT Evaluation of Neovascular AMD in Clinical Trials" spawned some great discussion. Watch a clip from the webinar video where we answer the participant question, "What are your thoughts on the use of AI for the interpretation of OCTs?" You can also watch the entire webinar on-demand [here](#).



Traveling to Seattle for ARVO 2024 next month? Our team would welcome the opportunity to connect (or reconnect) with you! [Set up a meeting](#) in advance.



EXECUTIVE SPOTLIGHT

MERIT Executive Spotlight is a series featuring leadership team members introducing themselves and explaining why they chose to work in the clinical trials industry and at MERIT. With 25+ years of experience in R&D and clinical trials within both biotech and leading pharma organizations, Dr. David Huang has taken responsibility for innovative Multi-Regional Clinical Trials (MRCT) from the IND stage to the NDA filing.


"As General Manager, I'm responsible for global strategy alignment and localization execution for MERIT's China team. Collaboration between business development, project management, and imaging quality control is crucial to our effective partnerships with Sponsors and CROs." [Read more.](#)



David Huang, MD, PhD, MS
General Manager China

OPHTHALMOLOGY SCIENTIFIC ADVISORY COUNCIL

Our Ophthalmology Scientific Advisory Council (SAC) advises MERIT on cutting edge technology and treatments to keep our firm aligned with market needs and assist with fulfilling our mission of driving innovation in life sciences.



Antonio Capone Jr., MD

We are fortunate to have Dr. Antonio Capone Jr. on our SAC. Dr. Capone is an internationally recognized clinician, surgeon, and educator specializing in pediatric vitreoretinal diseases, complicated retinal detachment, ocular oncology, and macular disease.



Theodore Leng, MD, MS

We are privileged to have Dr. Theodore Leng on our SAC. Dr. Leng's research focuses on cellular, biologic, and laser-based therapies for macular degeneration. He is also a KOL in artificial intelligence and data science. Dr. Leng has applied AI, web3, and real-world evidence generation to further bioscience research, development programs, and clinical care.

[LEARN MORE ABOUT MERIT'S SAC](#)

MERIT's Solutions Guides offer an in-depth look at MERIT's services, capabilities, and expertise. Check them [out!](#)



EMPLOYEE SPOTLIGHT

MERIT Employee Spotlight is a series featuring team members introducing themselves, outlining their role at MERIT, and explaining why they chose to work in the clinical trials industry.

"I thoroughly enjoy my work environment, particularly the friendship with my colleagues and the overall positive atmosphere. Contributing to clinical trials is deeply rewarding, knowing that my efforts play a part in advancing medical research and improving patient outcomes." [Read More.](#)



Stephanie Jacoby
Project Manager III

RECENT INDUSTRY NEWS

Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24

Fierce Biotech's take on putting IPO and M&A deal activity into context. [Read more here.](#)

6 Recently Approved Cell & Gene Therapies—And Why They Matter

BioSpace's view on the importance of the big cell and gene therapy approvals of 2023 including Casgevy and Breyanzi and some upcoming potential approvals. [Read more here.](#)

US FDA approves Merck's therapy for rare lung condition

At the end of March, the US FDA approved Merck's treatment for Pulmonary Arterial Hypertension (PAH). Caused by a constriction of arteries in the lungs, PAH leads to high blood pressure, shortness of breath, chest pain and dizziness. [Read more here.](#)

COPD Market Poised for 'Paradigm Shift' with Potential Approvals in 2024: GlobalData

BioSpace examines whether potential FDA approvals for Sanofi and Regeneron's Dupixent and Verona's ensifentrine will change the landscape of COPD treatment. [Read more here.](#)

More FDA News and Notes for April

An at-a-glance summary of news from around the Agency thus far in April. [Click here](#) to read the press release.

UPCOMING CONFERENCES

We love meeting Sponsors, partners, and industry professionals! Network with us at one of our upcoming conferences or trade shows. You can set up an appointment with one of our team members by going to the [Events](#) page on our website and clicking on the event of interest!



ARVO
May 5-9, 2024 | Seattle, WA
Booth #1439



ATS
May 17-22, 2024 | San Diego, CA
Booth #3136



ASCO
May 31 - June 4, 2024 | Chicago, IL
Booth #11112



DIA
June 16-20, 2024 | San Diego, CA
Booth #2209

Feel free to forward our newsletter to any colleagues who might be interested. Thanks for reading!
[Subscribe](#) to stay up-to-date.



MERIT
meritcro.com
Phone: (608) 284-8810
Address: 6527 Normandy Lane, #100, Madison WI 53719



Twitter



LinkedIn



Youtube